Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

Biotechnology Institute IMASD

Status

Unknown

Conditions

Androgenetic Alopecia

Treatments

Other: Saline Solution

Device: PRGF-Endoret

Study type

Interventional

Funder types

Industry

Identifiers

BTI-01D-EC/12/ALO

Details and patient eligibility

About

Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals.
This clinical trial was designed to evaluate the efficacy and safety of using a preparation of autologous plasma rich in growth factors (PRGF-Endoret) in the treatment of androgenetic alopecia.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Exclusion criteria

No androgenetic alopecia
Telogen and anagen effluvium
Active inflammation or infection in the intervention area
Presence of active systemic infections.
Background of cancerous or precancerous lesions.
Background of connective or rheumatic diseases.
Suffering from any serious blood disorders.
To have undergone treatments for alopecia in the previous 6 months.
Previous hair implants
Intake of drugs that affect hair loss.
Be undergoing immunosuppressive therapy and/or anticoagulants.
Known intolerance to mesotherapy.
Taking contraceptives containing cyproterone acetate.
Pregnancy
In general, any limitations that would prevent the proper application of both treatments and the right monitoring of the efficacy variables.